RNAi-induced K-Ras gene silencing suppresses growth of EC9706 cells and enhances chemotherapy sensitivity of esophageal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6517-6521

  Wang, Xin Jie ^a   Zheng, Yu Ling ^a   Fan, Qing Xia ^a   Zhagn, Xu Dong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Chemotherapy sensitivity; Esophageal cancer; K Ras; Paclitaxel; RNAi

Indexed keywords

MESSENGER RNA; PACLITAXEL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECT; ESOPHAGUS TUMOR; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; METHODOLOGY; ONCOGENE RAS; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; GENE SILENCING; GENES, RAS; HUMANS; PACLITAXEL; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84877038628     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6517     Document Type: Article

References (21)

1. Akkiprik M, Celikel CA, Düsünceli F, et al (2008). Relationship between overexpression of Ras p21 oncoprotein and K-Ras codon 12 and 13 mutations in Trukish colorectal cancer patients. Turk J Gastroenterol, 19, 22-7.
2. Bivona TG, Quatela SE, Bodemann BO, et al (2006). PKC regulates a farne-syl-electro-soatic switch on K-Ras that promotes its association with Bcl-X2 on mitochondria and induces apoptosis [J]. Molecular Cell, 21, 481.
3. Chen Y, Lan Z, Hui Q, Li B, Yang Y (2008). Expression of RASSF1A and CyclinD1 in tissues with gastric mucosa lesion and their relationship. World Chin J Digestology, 16, 2604-9.
4. Cong DG, Wang SF, Zhang TW (2006). mRNA expression of RASSF1A in esophageal squamous cell carcinoma and clinical significance thereof. Nat Med J China, 86, 1624-7.
5. Leung RK, Whittaker PA (2005). RNA interference:from gene silencing to gene-specific therapeutics. Pharmacol Ther, 107, 222-39.
6. Li J, Zhao Z, Zhou Q, Wang L (2009). Expression of Ras protein in esophageal cancer and precancerous lesions. Chin J Clin Oncol Rehab, 6, 11-13.
7. Lo PH, Xie D, Chan KC, et al (2007). Reduced expression of RASSF1A in esophageal and naso-pharyngeal carcinomas significantly correlates with tumor stage. Cancer Lett, 257, 199-205.
8. Pijnenborg JM, Dam-de Veen GC, Kisters N, et al (2007). RASSF1A methylation and K-Ras and B-rafmutations and recurrent endometrial cancer. Ann Oncol, 18, 491-7.
9. Pu H, Chen X, Li X, et al (2011). Expression of hMLH1 and RASSF1A in esophageal cancer tissues and its relationship with prognosis. World Chin J Digestol, 19, 1347-52.
10. Quinlan MP, Settleman J (2008). A KRas-specific Function in cancer Initiation. Chin J Cancer, 27, 673.
11. Riely GJ, Marks J, Pao W (2009). K-RAS mutations in non-small cell lung cancer. Proc Am Thorac Soc, 6, 201-5.
12. Schimanski CC, Zimmermann T, Schmidtmann I, et al (2010). K-Ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFR alpha in colorectal cancer. Int J Colorectal Dis, 25, 181-6.
13. Shen YM, Yang XC, Yang C, Shen JK (2008). Enhanced therapeutic effects for human pancreatic cancer by application K-Ras and IGF-IR antisense Oligodeoxynucleotids. World J Gastroentero, 14, 5176-85.
14. Song MS, Chang JS, Song SJ, et al (2005). The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles. J Biol Chem, 280, 3920-7.
15. Stella G, Rojas FL, Barone C, et al (2009). KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients [C], ASCO GICancers Symposium, Abstr34.
16. Tanaka T, Ishiguro H, Kuwabara Y, et al (2010). Vascular endothelial growth factor C in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res, 29, 83.
17. Wang X, Zheng Y, Fan Q (2011). Ras pathway and the activated expression of cyclin D1 in esophageal squamous cell carcinoma. J Third Military Med University, 33, 2626-8.
18. Wang YX, Gao L, Ji ZZ (2007). Inhibitaary effects of antisense oligonucleoti-de specific to K-Ras pointmutation on the target gene expression in uman pancreatic carcinoma cells [J]. Chin Med J, 120, 1448.
19. Yoo YA, Na AR, Lee MS, et al (2006). RASSF1A suppresses oncogenic H-Ras-induced c-Jun N-terminal kinase activation. Int J Oncol, 29, 1541-7.
20. Zhang TW, Wang SF, Cong DG, et al (2007). Suppression of RASSF1A gene on human esophageal carcinoma cells: experiments in vitroR and in vivo. National Med J China, 87, 1214-6.
21. Zhong YQ, Xia ZS, Fu YR, et al (2010). Knockdown of Htert by siRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2. J Dig Dis, 11, 176-84